Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Anticipates Growth In 2005 From Zithromax, Zofran Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

PBM cites anticipated contribution to growth from several first-time generics that could enter the market in 2005. Nevertheless, Express Scripts concedes that generic utilization growth will be weaker in 2005 than in other years. Subsidiary CuraScript will aid PBM's growth by converting clients that use an outside specialty pharmacy provider.

You may also be interested in...



PBMs Eye Acquisitions In “Target-Rich Environment”

Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.

PBMs Eye Acquisitions In “Target-Rich Environment”

Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.

Generic Drug Price War Could Pay Off For PBMs

Pharmacy benefit managers earn higher profits on generics over brand products, Express Scripts CEO Toan says, and lower prices will lead to increased generic utilization. Caremark has gotten “some pickup” from the pricing competition, CEO Crawford says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel